SCHEMBL13093998

SCHEMBL13093998

C[C@@H](c1cnccn1)C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HSP90AA1 P07900 1/20 0.34
LMNA P02545 1/20 0.34
ATM Q13315 1/20 0.33
CYP2D6 P10635 3/20 0.32
HRH1 P35367 3/20 0.32
KCNH2 Q12809 2/20 0.32
CHRM1 P11229 1/20 0.32
LONP1 P36776 1/20 0.31
NAPRT Q6XQN6 1/20 0.30
HCAR2 Q8TDS4 1/20 0.30
NPC1 O15118 1/20 0.30
TP53 P04637 1/20 0.30
MAPT P10636 1/20 0.30
NFKB1 P19838 1/20 0.30
RAB9A P51151 1/20 0.30
NFKB2 Q00653 1/20 0.30
RELA Q04206 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5960485 1.00 KDM4E (0.35) KDM4ESMN1; SMN2ALDH1A1HSP90AA1LMNA
SCHEMBL10103672 1.00 KDM4E (0.35) KDM4ESMN1; SMN2ALDH1A1HSP90AA1LMNA
SCHEMBL28182368 0.81 LMNA (0.37) KDM4ESMN1; SMN2ALDH1A1HSP90AA1LMNA
SCHEMBL28182369 0.81 LMNA (0.37) KDM4ESMN1; SMN2ALDH1A1HSP90AA1LMNA
SCHEMBL9963353 0.77 KDM4E (0.37) KDM4ESMN1; SMN2ALDH1A1HSP90AA1LMNA
SCHEMBL18714321 0.77 KDM4E (0.37) KDM4ESMN1; SMN2ALDH1A1HSP90AA1LMNA
SCHEMBL20327882 0.77 KDM4E (0.37) KDM4ESMN1; SMN2ALDH1A1HSP90AA1LMNA
SCHEMBL10388192 0.77 KDM4E (0.38) KDM4ESMN1; SMN2ALDH1A1HSP90AA1LMNA
SCHEMBL29738290 0.77
SCHEMBL681871 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247401-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2012-08-21 US disclosed
US-20100266714-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME LLC 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266714-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN P2RX3, P2RX1, P2RX2 KDM4E 4010/4885SMN1; SMN2 1758/4885ALDH1A1 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.